Hexagon Bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
90
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$77.3M
- Investors
-
14
Hexagon Bio General Information
Description
Developer of synthetic biology platform designed to use data science to search for genomes for small molecule inhibitors of selected target proteins. The company's platform uses genomics, synthetic biology, and automation to discover evolutionarily refined molecules and their protein targets directly from fungal genomes for identifying medicines encoded in the global metagenome, enabling researchers to find a way to develop new medicines to improve the lives of the patients.
Contact Information
Website
www.hexagonbio.comCorporate Office
- 1490 O'Brien Drive
- Suite E
- Menlo Park, CA 94025
- United States
Hexagon Bio Timeline
Hexagon Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 13-Feb-2023 | $77.3M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series A) | 22-Sep-2021 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A1) | 15-Sep-2020 | $47M | $55.3M | 0000 | Completed | Clinical Trials - General |
| 1. Seed Round | 18-Jul-2017 | $8.3M | $8.3M | 000.00 | Completed | Clinical Trials - General |
Hexagon Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-Prime | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A1 | 18,250,075 | $0.000100 | 8% | $1.92 | $1.92 | 1x | $1.92 | 23.38% |
| Seed | 3,256,567 | $0.000100 | 8% | $2.58 | $2.58 | 1x | $2.58 | 4.17% |
Hexagon Bio Comparisons
Industry
Financing
Details
000 00
00000
Hexagon Bio Competitors (50)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| Cyclica | Formerly VC-backed | Toronto, Canada | 00 | 000.00 | 000000&0 | 000.00 |
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | 000 | 00.000 | 00000000 | 00.000 |
| Ribometrix | Venture Capital-Backed | Durham, NC | 00 | 000.00 | 0000000000 0 | 000.00 |
Hexagon Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hexagon Bio Executive Team (10)
Hexagon Bio Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Kolicich | 8VC | Board Member | 000 0000 |
| Brian Naughton Ph.D | Hexagon Bio | Co-Founder, Chief Technology Officer, Board Member & Head of Data | 000 0000 |
| Colin Harvey Ph.D | Hexagon Bio | Co-Founder, Vice President of Synthetic Biology& Board Member | 000 0000 |
| David Goeddel Ph.D | The Column Group | Chairman | 000 0000 |
| Jakob Loven Ph.D | Nextech Invest | Board Member | 000 0000 |
Hexagon Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Hexagon Bio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| bpd partners | Family Office | Minority | 000 0000 | 000000 0 | |
| CPP Investments | Limited Partner | Minority | 000 0000 | 000000 0 | |
| Casdin Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Nextech Invest | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SoftBank Investment Advisers | Growth/Expansion | Minority | 000 0000 | 000000 0 |
Hexagon Bio FAQs
-
When was Hexagon Bio founded?
Hexagon Bio was founded in 2016.
-
Who is the founder of Hexagon Bio?
Maureen Hillenmeyer Ph.D, Brian Naughton Ph.D, Yi Tang Ph.D, and Colin Harvey Ph.D are the founders of Hexagon Bio.
-
Who is the CEO of Hexagon Bio?
Maureen Hillenmeyer Ph.D is the CEO of Hexagon Bio.
-
Where is Hexagon Bio headquartered?
Hexagon Bio is headquartered in Menlo Park, CA.
-
What is the size of Hexagon Bio?
Hexagon Bio has 90 total employees.
-
What industry is Hexagon Bio in?
Hexagon Bio’s primary industry is Drug Discovery.
-
Is Hexagon Bio a private or public company?
Hexagon Bio is a Private company.
-
What is the current valuation of Hexagon Bio?
The current valuation of Hexagon Bio is 00000.
-
What is Hexagon Bio’s current revenue?
The current revenue for Hexagon Bio is 000000.
-
How much funding has Hexagon Bio raised over time?
Hexagon Bio has raised $194M.
-
Who are Hexagon Bio’s investors?
bpd partners, CPP Investments, Casdin Capital, Nextech Invest, and SoftBank Investment Advisers are 5 of 14 investors who have invested in Hexagon Bio.
-
Who are Hexagon Bio’s competitors?
Exo Therapeutics, Relay Therapeutics, Cyclica, Kymera Therapeutics, and Ribometrix are some of the 50 competitors of Hexagon Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
